$6.64
1.68% yesterday
Nasdaq, May 20, 10:00 pm CET
ISIN
US04335A1051
Symbol
ARVN
Sector
Industry

Arvinas, Inc. Stock price

$6.64
-2.11 24.11% 1M
-16.05 70.74% 6M
-12.53 65.36% YTD
-26.62 80.04% 1Y
-38.00 85.13% 3Y
-37.73 85.03% 5Y
-9.41 58.63% 10Y
Nasdaq, Closing price Tue, May 20 2025
+0.11 1.68%
ISIN
US04335A1051
Symbol
ARVN
Sector
Industry

Key metrics

Market capitalization $484.66m
Enterprise Value $-544.84m
P/E (TTM) P/E ratio negative
EV/Sales (TTM) EV/Sales -3.38
P/S ratio (TTM) P/S ratio 3.01
P/B ratio (TTM) P/B ratio 0.73
Revenue growth (TTM) Revenue growth 105.10%
Revenue (TTM) Revenue $161.00m
Cash position $954.30m
EPS (TTM) EPS $-2.08
P/E forward negative
P/S forward 1.69
EV/Sales forward negative
Short interest 10.30%
Show more

Is Arvinas, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Arvinas, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

21 Analysts have issued a Arvinas, Inc. forecast:

13x Buy
62%
8x Hold
38%

Analyst Opinions

21 Analysts have issued a Arvinas, Inc. forecast:

Buy
62%
Hold
38%

Financial data from Arvinas, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
161 161
105% 105%
100%
- Direct Costs 5 5
25% 25%
3%
161 161
124% 124%
100%
- Selling and Administrative Expenses - -
-
-
- Research and Development Expense - -
-
-
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT - -
-
-
Net Profit -150 -150
59% 59%
-93%

In millions USD.

Don't miss a Thing! We will send you all news about Arvinas, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Arvinas, Inc. Stock News

Neutral
GlobeNewsWire
15 days ago
NEW YORK , May 05, 2025 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Arvinas, Inc. (“Arvinas” or the “Company”) (NASDAQ:ARVN). The investigation concerns whether Arvinas and/or certain of its officers have violated the federal securities laws.
Neutral
Seeking Alpha
16 days ago
I favor biotech stocks trading below cash value after setbacks; Arvinas (ARVN) fits this description, dropping 25% on Thursday after ending two Phase 3 trials. ARVN's net cash per share is over $12, presenting a 70% upside from its current $7 stock price. ARVN's remaining pipeline holds minimal value; the investment thesis hinges on its substantial cash reserves and potential for activist share...
Neutral
Accesswire
19 days ago
BOSTON, MA / ACCESS Newswire / May 2, 2025 / Block & Leviton is investigating Arvinas, Inc. (Nasdaq:ARVN) for potential securities law violations. Investors who have lost money in their Arvinas, Inc. investment should contact the firm to learn more about how they might recover those losses.
More Arvinas, Inc. News

Company Profile

Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of therapies to degrade disease-causing proteins. Its lead products include ARV-110 and ARV-471. The company was founded in February 2013 and is headquartered in New Haven, CT.

Head office United States
CEO John Houston
Employees 430
Founded 2013
Website www.arvinas.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today